ABIONYX PHARMA financials
ABIONYX PHARMA
969500785J7VIC5YPC96 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €4.1M | €4.6M |
| Cost of sales | €3.5M | €3.7M |
| Operating profit (EBIT) | -€5.5M | -€4.5M |
| Net finance income / (cost) | -€3.0K | €84.0K |
| Finance costs | €159.0K | €132.0K |
| Income tax expense | €9.0K | €0 |
| Profit for the year | -€5.5M | -€4.4M |
| Total comprehensive income | -€5.6M | -€4.3M |
| Per share | ||
| Basic EPS | €-0.16 | €-0.13 |
| Diluted EPS | €-0.16 | €-0.13 |
| Free cash flow / share | €-0.08 | €-0.10 |
| Cash flow statement | ||
| Net cash from operating activities | -€2.9M | -€3.6M |
| Net cash from investing activities | -€205.0K | -€76.0K |
| Purchase of PP&E (capex) | €242.0K | €68.0K |
| Purchase of intangibles | €0 | €8.0K |
| Net cash from financing activities | €3.4M | €2.8M |
| Net change in cash | €287.0K | -€866.0K |
| Balance sheet | ||
| Total assets | €13.1M | €13.5M |
| Non-current assets | €7.6M | €7.7M |
| Property, plant & equipment | €400.0K | €278.0K |
| Right-of-use assets | €1.4M | €1.7M |
| Intangible assets & goodwill | €5.4M | €5.4M |
| Current assets | €5.5M | €5.9M |
| Inventories | €255.0K | €211.0K |
| Cash & equivalents | €3.5M | €3.2M |
| Total equity | €4.5M | €7.5M |
| Non-current liabilities | €3.4M | €2.3M |
| Long-term borrowings | €2.0M | €611.0K |
| Lease liabilities (non-current) | €1.1M | €1.3M |
| Current liabilities | €5.2M | €3.7M |
| Lease liabilities (current) | €339.0K | €341.0K |
| Derived metrics | ||
| Free cash flow | -€3.2M | -€3.7M |
| Operating margin | -136.3% | -98.1% |
| Net margin | -136.6% | -96.3% |
| Return on equity | -123.0% | -58.3% |
| Cash conversion ratio | 0.53× | 0.83× |
| Capex coverage | -12.12× | -53.44× |
| Other reported items | ||
| Adjusted Weighted Average Shares | 38.3M | 36.1M |
| Adjustments For Depreciation and Amortisation Expense | €126.0K | €135.0K |
| Adjustments For Income Tax Expense | -€9.0K | €0 |
| Adjustments For Increase Decrease In Deferred Income Other Than Contract Liabilities | -€93.0K | €0 |
| Adjustments For Provisions | €128.0K | -€20.0K |
| Adjustments For Sharebased Payments | €792.0K | €626.0K |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €3.5M | €3.2M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€4.5M | -€3.6M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €453.0K | €502.0K |
| Current Provisions | €76.0K | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €0 | €0 |
| Equity and Liabilities | €13.1M | €13.5M |
| Finance Income | €156.0K | €216.0K |
| Income Taxes Paid Refund Classified As Operating Activities | -€9.0K | €0 |
| Increase Decrease In Number of Ordinary Shares Issued | 0.6M | 2.5M |
| Increase Decrease In Working Capital | -€1.6M | €28.0K |
| Increase Decrease Through Sharebased Payment Transactions | €792.0K | €626.0K |
| Increase Decrease Through Transfers and Other Changes Equity | -€19.0K | €0 |
| Increase Decrease Through Treasury Share Transactions | €169.0K | -€58.0K |
| Intangible Assets Other Than Goodwill | €66.0K | €77.0K |
| Interest Paid Classified As Operating Activities | €0 | €0 |
| Issue of Equity | €1.7M | €3.4M |
| Issued Capital | €1.8M | €1.7M |
| Noncurrent Provisions For Employee Benefits | €427.0K | €407.0K |
| Number of Shares Issued | 35.5M | 34.9M |
| Other Adjustments For Noncash Items | -€32.0K | €0 |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€83.0K | €38.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €16.0K | €10.0K |
| Other Noncurrent Assets | €404.0K | €244.0K |
| Other Operating Income Expense | €20.0K | €21.0K |
| Proceeds From Government Grants Classified As Financing Activities | €514.0K | €0 |
| Proceeds From Issuing Shares | €1.7M | €3.4M |
| Proceeds From Sales of Intangible Assets Classified As Investing Activities | €0 | €0 |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €37.0K | €0 |
| Research and Development Expense | €1.5M | €1.9M |
| Reserve of Exchange Differences On Translation | €58.0K | €141.0K |
| Retained Earnings Profit Loss For Reporting Period | -€5.5M | -€4.4M |
| Selling General and Administrative Expense | €4.6M | €3.4M |
| Share Premium | €6.3M | €8.6M |
| Trade and Other Current Payables To Trade Suppliers | €1.5M | €1.6M |
| Weighted Average Shares | 35.0M | 33.7M |
Every line item above is a fact tagged in ABIONYX PHARMA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.